[en] Cervical cancer is the fourth most common cancer in women and is linked in over 95 % of cases to papillomavirus infection, the incidence of which has fallen in recent years due to screening and vaccination. Almost half of these cancers are diagnosed at a locally advanced stage with an overall 5-year survival of around 65 %. In recent decades, the management strategy of these locally advanced cancers has changed considerably and has allowed the improvement of survival but above all of local control as well as the reduction of toxicity, due to the implementation of imaging. Standard treatment consists of external beam radiation therapy combined with concomitant chemotherapy followed by intrauterine brachytherapy. The role of neo-adjuvant and adjuvant chemotherapy is still being evaluated. New therapeutic approaches (particularly immunotherapy) in addition to standard treatment are also being studied.
Disciplines :
Radiologie, médecine & imagerie nucléaire
Auteur, co-auteur :
LAPAILLE, Louis ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
DE CUYPERE, Marjolein ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Secteur oncologie
GOFFIN, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Secteur gynécologie
KAKKOS, Athanasios ; Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Secteur oncologie
GONNE, Elodie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
HERMESSE, Johanne ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de radiothérapie
LOVINFOSSE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de médecine nucléaire et imagerie onco
DELBECQUE, Katty ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Service d'anatomie et cytologie pathologiques
THILLE, Alain ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de radiodiagnostic
Kridelka, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-Obstétrique
GENNIGENS, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Langue du document :
Français
Titre :
Cancer du col utérin localement avancé : approche multidisciplinaire.
Titre traduit :
[en] Locally-advanced cervix cancer : multidisciplinary management
Date de publication/diffusion :
2021
Titre du périodique :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Maison d'édition :
Université de Liège. Revue Médicale de Liège, Liège, Belgique
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019;393:169-82.
Zappa M, Visioli CB, Ciatto S, et al. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004;90:1784-6.
Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer 2018;28:641-55.
Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129-35.
No authors listed. Corrigendum to «Revised FIGO staging for carcinoma of the cervix uteri» [Int J Gynecol Obstet 145(2019) 129-35]. Int J Gynaecol Obstet 2019;147:279-80.
Haldorsen IS, Lura N, Blaakær J, et al. What is the role of imaging at primary diagnostic work-up in uterine cervical cancer? Curr Oncol Rep 2019;21:77.
Thomeer MG, Gerestein C, Spronk S, et al. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol 2013;23:2005-18.
Knoth J, Pötter R, Jürgenliemk-Schulz IM, et al. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study. Gynecol Oncol 2020;159:136-41.
Atri M, Zhang Z, Dehdashti F, et al. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol 2016;142:413-9.
De Cuypere M, Lovinfosse P, Goffin F, et al. Added value of para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. Eur J Surg Oncol 2020;46:883-7.
Martinez A, Voglimacci M, Lusque A, et al. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging 2020;47:1252-60.
Gee MS, Atri M, Bandos AI, et al. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology 2018;287:176-84.
Gennigens C, De Cuypere M, Hermesse J, et al. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther 2021; doi: 10.1080/14737140.2021.
Yeung AR, Pugh SL, Klopp AH, et al. Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study. J Clin Oncol 2020;38:1685-92.
Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol 2018;13:177.
Lin AJ, Kidd E, Dehdashti F, et al. Intensity modulated radiation therapy and image-guided adapted brachytherapy for cervix cancer. Int J Radiat Oncol Biol Phys 2019;103:1088-97.
Viani GA, Dos Santos FM, Pavoni JF. Significant impact on the oncologic outcomes with intensity modulated radiotherapy and conformational radiotherapy over conventional radiotherapy in cervix cancer patients treated with radiotherapy. Rep Pract Oncol Radiother 2020;25:678-83.
Tan LT, Tanderup K, Kirisits C, et al. Image-guided adaptive radiotherapy in cervical cancer. Semin Radiat Oncol 2019;29:284-98.
Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 2012;103:305-13.
Castelnau-Marchand P, Chargari C, Maroun P, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol 2015;139:288-94.
Pötter R, Georg P, Dimopoulos JC, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 2011;100:116-23.
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12.
Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010;2010:CD008285.
Datta NR, Stutz E, Liu M, et al. Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis. Gynecol Oncol 2017;145:374-85.
Schmid MP, Franckena M, Kirchheiner K, et al. Distant metastasis in patients with cervical cancer after primary radiotherapy with or without chemotherapy and image guided adaptive brachytherapy. Gynecol Oncol 2014;133:256-62.
Escande A, Khettab M, Bockel S, et al. Interaction between the number of chemotherapy cycles and brachytherapy dose/volume parameters in locally advanced cervical cancer patients. J Clin Med 2020;9:1653.
Ma S, Wang J, Han Y, et al. Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials. Gynecol Oncol 2019;154:246-52.
Zhu J, Zhang Z, Bian D, et al. Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: an updated meta-analysis based on randomized controlled trials. Medicine (Baltimore) 2020;99:e18663.
Tanderup K, Fokdal LU, Sturdza A, et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 2016;120:441-6.
Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 2007;83:148-55.
Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1226-32.
Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011;29:1678-85.
Tang J, Tang Y, Yang J, Huang S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 2012;125:297-302.
Mahmoud O, Einstein MH. Which patients with cervical squamous cell carcinoma might benefit from neoadjuvant chemotherapy? J Clin Oncol 2018;36:1543-7.
Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, et al. Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol 2006;100:338-43.
Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist 2012;17:64-71.
Ferrandina G, Ercoli A, Fagotti A, et al. Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications. Ann Surg Oncol 2014;21:1692-9.
Varela Cagetti L, Zemmour C, Minsat M, et al. Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy. Gynecol Oncol 2020;156:328-34.
Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Guidelines insights: Cervical cancer, Version 1.2020. J Natl Compr Canc Netw 2020;18:660-66.
Valduvieco I, Biete A, Rios I, et al. Correlation between clinical findings and magnetic resonance imaging for the assessment of local response after standard treatment in cervical cancer. Rep Pract Oncol Radiother 2013;18:214-9.
Vincens E, Balleyguier C, Rey A, et al. Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: correlation of radiologic findings with surgicopathologic results. Cancer 2008;113:2158-65.
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2012;83:185-90.
Lima GM, Matti A, Vara G, et al. Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging 2018;45:2139-46.
Scher N, Castelli J, Depeursinge A, et al. (18F)-FDG PET/CT parameters to predict survival and recurrence in patients with locally advanced cervical cancer treated with chemoradiotherapy. Cancer Radiother 2018;22:229-35.
Verma J, Monk BJ, Wolfson AH. New strategies for multimodality therapy in treating locally advanced cervix cancer. Semin Radiat Oncol 2016;26:344–8.
Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.
Schefter T, Winter K, Kwon JS, et al. Radiation Therapy Oncology Group (RTOG). RTOG 0417: Efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014;88:101-5.
Cohen AC, Roane BM, Leath CA 3rd. Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy. Drugs 2020;80:217-27.
Yang W, Lu YP, Yang YZ, et al. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res 2017;43:1602-12.
Mayadev J, Nunes AT, Li M, et al. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer 2020;30:1065-70.
Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 2018;28:764-72.
Mayor P, Starbuck K, Zsiros E. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 2018;150:361-9.
Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol 2019;37:2538.
Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med 1999;340:1383-9.
Schover LR, Fife M, Gershenson DM. Sexual dysfunction and treatment for early stage cervical cancer. Cancer 1989;63:204-12.
Korfage IJ, Essink-Bot ML, Mols F, et al. Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys 2009;73:1501-9.
Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-36.
Hoekman EJ, Broeders EA, Louwe LA, et al. Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. Eur J Surg Oncol 2019;45:1328-40.
Brennan A, Brennan D, Rees M, Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int J Gynecol Cancer 2021;31:352-9.
Verjans J, Kridelka F, De Cuypere M, Gennigens C. Locally advanced cervical cancer: a descriptive analysis of 20 patients with a visceral recurrence. Eur J Obstet Gynecol Reprod Biol 2020;2:255-61.
